Dihydro-CDDO-trifluoroethyl amide (dh404), a novel Nrf2 activator, suppresses oxidative stress in cardiomyocytes.

Targeting Nrf2 signaling appears to be an attractive approach for the treatment of maladaptive cardiac remodeling and dysfunction; however, pharmacological modulation of the Nrf2 pathway in the cardiovascular system remains to be established. Herein, we report that a novel synthetic triterpenoid der...

Full description

Bibliographic Details
Main Authors: Tomonaga Ichikawa, Jinqing Li, Colin J Meyer, Joseph S Janicki, Mark Hannink, Taixing Cui
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2009-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC2791441?pdf=render
id doaj-66fc5dd01b224c0f83669f1b7b400c41
record_format Article
spelling doaj-66fc5dd01b224c0f83669f1b7b400c412020-11-25T02:21:17ZengPublic Library of Science (PLoS)PLoS ONE1932-62032009-01-01412e839110.1371/journal.pone.0008391Dihydro-CDDO-trifluoroethyl amide (dh404), a novel Nrf2 activator, suppresses oxidative stress in cardiomyocytes.Tomonaga IchikawaJinqing LiColin J MeyerJoseph S JanickiMark HanninkTaixing CuiTargeting Nrf2 signaling appears to be an attractive approach for the treatment of maladaptive cardiac remodeling and dysfunction; however, pharmacological modulation of the Nrf2 pathway in the cardiovascular system remains to be established. Herein, we report that a novel synthetic triterpenoid derivative, dihydro-CDDO-trifluoroethyl amide (dh404), activates Nrf2 and suppresses oxidative stress in cardiomyocytes. Dh404 interrupted the Keap1-Cul3-Rbx1 E3 ligase complex-mediated Nrf2 ubiquitination and subsequent degradation saturating the binding capacity of Keap1 to Nrf2, thereby rendering more Nrf2 to be translocated into the nuclei to activate Nrf2-driven gene transcription. A mutant Keap1 protein containing a single cysteine-to-serine substitution at residue 151 within the BTB domain of Keap1 was resistant to dh404-induced stabilization of Nrf2 protein. In addition, dh404 did not dissociate the interaction of Nrf2 with the Keap1-Cul3-Rbx1 E3 ligase complex. Thus, it is likely that dh404 inhibits the ability of Keap1-Cul3-Rbx1 E3 ligase complex to target Nrf2 for ubiquitination and degradation via modifying Cys-151 of Keap1 to change the conformation of the complex. Moreover, dh404 was able to stabilize Nrf2 protein, to enhance Nrf2 nuclear translocation, to activate Nrf2-driven transcription, and to suppress angiotensin II (Ang II)-induced oxidative stress in cardiomyocytes. Knockdown of Nrf2 almost blocked the anti-oxidative effect of dh404. Dh404 activated Nrf2 signaling in the heart. Taken together, dh404 appears to be a novel Nrf2 activator with a therapeutic potential for cardiac diseases via suppressing oxidative stress.http://europepmc.org/articles/PMC2791441?pdf=render
collection DOAJ
language English
format Article
sources DOAJ
author Tomonaga Ichikawa
Jinqing Li
Colin J Meyer
Joseph S Janicki
Mark Hannink
Taixing Cui
spellingShingle Tomonaga Ichikawa
Jinqing Li
Colin J Meyer
Joseph S Janicki
Mark Hannink
Taixing Cui
Dihydro-CDDO-trifluoroethyl amide (dh404), a novel Nrf2 activator, suppresses oxidative stress in cardiomyocytes.
PLoS ONE
author_facet Tomonaga Ichikawa
Jinqing Li
Colin J Meyer
Joseph S Janicki
Mark Hannink
Taixing Cui
author_sort Tomonaga Ichikawa
title Dihydro-CDDO-trifluoroethyl amide (dh404), a novel Nrf2 activator, suppresses oxidative stress in cardiomyocytes.
title_short Dihydro-CDDO-trifluoroethyl amide (dh404), a novel Nrf2 activator, suppresses oxidative stress in cardiomyocytes.
title_full Dihydro-CDDO-trifluoroethyl amide (dh404), a novel Nrf2 activator, suppresses oxidative stress in cardiomyocytes.
title_fullStr Dihydro-CDDO-trifluoroethyl amide (dh404), a novel Nrf2 activator, suppresses oxidative stress in cardiomyocytes.
title_full_unstemmed Dihydro-CDDO-trifluoroethyl amide (dh404), a novel Nrf2 activator, suppresses oxidative stress in cardiomyocytes.
title_sort dihydro-cddo-trifluoroethyl amide (dh404), a novel nrf2 activator, suppresses oxidative stress in cardiomyocytes.
publisher Public Library of Science (PLoS)
series PLoS ONE
issn 1932-6203
publishDate 2009-01-01
description Targeting Nrf2 signaling appears to be an attractive approach for the treatment of maladaptive cardiac remodeling and dysfunction; however, pharmacological modulation of the Nrf2 pathway in the cardiovascular system remains to be established. Herein, we report that a novel synthetic triterpenoid derivative, dihydro-CDDO-trifluoroethyl amide (dh404), activates Nrf2 and suppresses oxidative stress in cardiomyocytes. Dh404 interrupted the Keap1-Cul3-Rbx1 E3 ligase complex-mediated Nrf2 ubiquitination and subsequent degradation saturating the binding capacity of Keap1 to Nrf2, thereby rendering more Nrf2 to be translocated into the nuclei to activate Nrf2-driven gene transcription. A mutant Keap1 protein containing a single cysteine-to-serine substitution at residue 151 within the BTB domain of Keap1 was resistant to dh404-induced stabilization of Nrf2 protein. In addition, dh404 did not dissociate the interaction of Nrf2 with the Keap1-Cul3-Rbx1 E3 ligase complex. Thus, it is likely that dh404 inhibits the ability of Keap1-Cul3-Rbx1 E3 ligase complex to target Nrf2 for ubiquitination and degradation via modifying Cys-151 of Keap1 to change the conformation of the complex. Moreover, dh404 was able to stabilize Nrf2 protein, to enhance Nrf2 nuclear translocation, to activate Nrf2-driven transcription, and to suppress angiotensin II (Ang II)-induced oxidative stress in cardiomyocytes. Knockdown of Nrf2 almost blocked the anti-oxidative effect of dh404. Dh404 activated Nrf2 signaling in the heart. Taken together, dh404 appears to be a novel Nrf2 activator with a therapeutic potential for cardiac diseases via suppressing oxidative stress.
url http://europepmc.org/articles/PMC2791441?pdf=render
work_keys_str_mv AT tomonagaichikawa dihydrocddotrifluoroethylamidedh404anovelnrf2activatorsuppressesoxidativestressincardiomyocytes
AT jinqingli dihydrocddotrifluoroethylamidedh404anovelnrf2activatorsuppressesoxidativestressincardiomyocytes
AT colinjmeyer dihydrocddotrifluoroethylamidedh404anovelnrf2activatorsuppressesoxidativestressincardiomyocytes
AT josephsjanicki dihydrocddotrifluoroethylamidedh404anovelnrf2activatorsuppressesoxidativestressincardiomyocytes
AT markhannink dihydrocddotrifluoroethylamidedh404anovelnrf2activatorsuppressesoxidativestressincardiomyocytes
AT taixingcui dihydrocddotrifluoroethylamidedh404anovelnrf2activatorsuppressesoxidativestressincardiomyocytes
_version_ 1724867245900824576